Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus as second-line therapy in urothelial transitional cell carcinoma
2010-020067-20Phase 2Completed
- Sponsor
- Hôpital Foch
- Start
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in transitional cell carcinoma (TCC), sponsored by Hôpital Foch. Primary endpoint: Progression-free survival. Started Jun 2010; status: completed.
02
Drugs
everolimus
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2010-020067-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020067-20.